Clinical trials · New York, NY
Metastatic Prostate Cancer clinical trials in New York
We’re tracking 142 recruiting metastatic prostate cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
New York, New YorkAges 18 years+ - NCT07184957Recruiting
Cryotherapy for localized prostate cancer: a data study
This study tracks outcomes for men who choose cryotherapy (freezing cancer cells) to treat prostate cancer that hasn't spread. It helps doctors understand how well this treatment works.
New York, New YorkAges 40–85 - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
New York, New YorkAges 18 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
New York, New YorkAges 18 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT06347705RecruitingPhase 2
Vaccine plus standard therapy for prostate cancer before surgery
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
New York, New YorkAges 18 years+ - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Long Island City, New YorkAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Belleville, New JerseyAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
The Bronx, New YorkAges 18 years+ - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
The Bronx, New YorkAges 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
The Bronx, New YorkAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
The Bronx, New YorkAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
The Bronx, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
The Bronx, New YorkAges 18 years+ - NCT07529717RecruitingPhase 1/Phase 2
Early-stage study of AZD8359 for advanced prostate cancer
This study tests a new experimental drug (AZD8359) designed to target prostate cancer cells in men whose cancer has progressed despite previous treatments. The drug works by directing immune cells to attack cancer cells.
Hackensack, New JerseyAges 18–100 - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Hackensack, New JerseyAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Hackensack, New JerseyAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Hackensack, New JerseyAges 18 years+ - NCT06496256Recruiting
Barrigel gel for radiation after prostate removal
This trial tests a gel placed in the rectum during radiation therapy to protect healthy tissue after prostate removal. It is for men whose prostate cancer has come back (PSA rise) and who need radiation to the prostate bed.
Clifton, New JerseyAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Lake Success, New YorkAges 18–99 - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
Lake Success, New YorkAges 18 years+ - NCT07824349RecruitingPhase 1
JUR-003 for metastatic prostate cancer
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Lake Success, New YorkAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Lake Success, New YorkAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 4 studies
- Montefiore Medical Center · 4 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 3 studies
- Hackensack University Medical Center · 2 studies
- James J. Peters VA Medical Center · 2 studies
- Montefiore Einstein Comprehensive Cancer Center · 2 studies
- Rutgers Cancer Institute of New Jersey · 2 studies
- AsteraCancer Care
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic prostate cancer studies in New York.
Common questions
- Are there metastatic prostate cancer clinical trials near New York?
- Yes. We're currently tracking 142 recruiting metastatic prostate cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.